Lynn Feun is an Oncology physician affiliated with University of Miami. OpenAlex indexes 338 publications with 8,720 citations (h-index 46); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1475 NW 12th Ave
Miami, FL 331361002
Telephone
305-243-6606Provider last certified this registry record 4 Nov 2022.
Clinical trials
- Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
Sponsor: University of Miami
- Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Sponsor: University of Miami
- Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma
Sponsor: Lynn Feun, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Iovance Biotherapeutics, Inc.Program year20251 payment
- JAZZ PHARMACEUTICALS INC.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
40.3%Opioid Agonist32.6%Oxycodone Hcl56%Tramadol Hcl44%Part D<11 patientsBenzodiazepine7.7%Alprazolam100%Part D<11 patientsHormonal (systemic)
34.4%l-Thyroxine34.4%Levothyroxine Sodium100%Part D≥22 patientsMetabolism & gastrointestinal
12.7%Serotonin-3 Receptor Antagonist6.8%Ondansetron Hcl100%Part D<11 patientsCorticosteroid5.9%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1993–2006 per NIH RePORTER. The latest:
- Arginine Deprivation: A targeted therapy for Melanoma
University of Miami School of Medicine
FY2006$199,719R01CA109578 - Arginine Deprivation: A targeted therapy for Melanoma
University of Miami School of Medicine
FY2005$204,525R01CA109578 - Arginine Deprivation: A targeted therapy for Melanoma
University of Miami School of Medicine
FY2004$204,525R01CA109578
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Carlos Singer
University of Miami
Jay Spiegel, MD
University of Miami
Kara Cavuoto, MD
University of Miami
Sixto Arias, MD
University of Miami
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”